Statins: Could an old friend help in the fight against COVID‐19?

The COVID‐19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID‐19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial ef...

Full description

Saved in:
Bibliographic Details
Published in:British journal of pharmacology 2020-11, Vol.177 (21), p.4873-4886
Main Authors: Rodrigues‐Diez, Raul R., Tejera‐Muñoz, Antonio, Marquez‐Exposito, Laura, Rayego‐Mateos, Sandra, Santos Sanchez, Laura, Marchant, Vanessa, Tejedor Santamaria, Lucía, Ramos, Adrian M., Ortiz, Alberto, Egido, Jesus, Ruiz‐Ortega, Marta
Format: Article
Language:English
Subjects:
ACE2
Angiotensin-converting enzyme 2
Animals
Autophagy
Betacoronavirus - isolation & purification
CD147 antigen
Coronavirus Infections - drug therapy
Coronavirus Infections - immunology
Coronavirus Infections - virology
Coronaviruses
COVID-19
COVID-19 Drug Treatment
Cytokine storm
Cytokines - immunology
Drug Repositioning
Epidemiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Inflammasomes
Inflammation
Lipid rafts
Molecular modelling
Pandemics
Phagocytosis
Pneumonia, Viral - drug therapy
Pneumonia, Viral - immunology
Pneumonia, Viral - virology
Replication
Review
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Statins
Themed Issue: Review
Virus Internalization - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5136-815459d436264d14fbdd9f3de695953f0448309103ea41bac212615445f9e3683
cites cdi_FETCH-LOGICAL-c5136-815459d436264d14fbdd9f3de695953f0448309103ea41bac212615445f9e3683
container_end_page 4886
container_issue 21
container_start_page 4873
container_title British journal of pharmacology
container_volume 177
creator Rodrigues‐Diez, Raul R.
Tejera‐Muñoz, Antonio
Marquez‐Exposito, Laura
Rayego‐Mateos, Sandra
Santos Sanchez, Laura
Marchant, Vanessa
Tejedor Santamaria, Lucía
Ramos, Adrian M.
Ortiz, Alberto
Egido, Jesus
Ruiz‐Ortega, Marta
description The COVID‐19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID‐19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID‐19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS‐CoV‐2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well‐known anti‐inflammatory properties of statins, by blocking several molecular mechanisms, including NF‐κB and NLRP3 inflammasomes, could limit the “cytokine storm” in severe COVID‐19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID‐19 outcomes. Linked Articles This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc
doi_str_mv 10.1111/bph.15166
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7323198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2415297031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5136-815459d436264d14fbdd9f3de695953f0448309103ea41bac212615445f9e3683</originalsourceid><addsrcrecordid>eNp1kclKxEAQhhtRdFwOvoA0eNFDnK7ekvag6LiCoOBybXqSzqQlk4zpRPHmI_iMPomtM4oK1qUO9dVHFT9C60B2IFR_OCl2QICUc6gHPJaRYAnMox4hJI4AkmQJLXt_T0gYxmIRLTEqJKWx7KHD69a0rvK7eFB3ZYZNhevQ8sbZKsOFLSfYVbgtLM7dqGixGZlAt3hweXd-9PbyCmp_FS3kpvR2bdZX0O3J8c3gLLq4PD0fHFxEqQAmowQEFyrjTFLJM-D5MMtUzjIrlVCC5YTzhBEFhFnDYWhSClSGHS5yZZlM2Aram3on3XBss9RWbWNKPWnc2DTPujZO_55UrtCj-lHHjDJQH4KtmaCpHzrrWz12PrVlaSpbd15TDoKqmDAI6OYf9L7umiq8FygBCiSLRaC2p1Ta1N43Nv8-Boj-SEaHZPRnMoHd-Hn9N_kVRQD6U-DJlfb5f5M-vDqbKt8B2-6VHw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451916375</pqid></control><display><type>article</type><title>Statins: Could an old friend help in the fight against COVID‐19?</title><source>Wiley</source><source>PubMed Central(OpenAccess)</source><creator>Rodrigues‐Diez, Raul R. ; Tejera‐Muñoz, Antonio ; Marquez‐Exposito, Laura ; Rayego‐Mateos, Sandra ; Santos Sanchez, Laura ; Marchant, Vanessa ; Tejedor Santamaria, Lucía ; Ramos, Adrian M. ; Ortiz, Alberto ; Egido, Jesus ; Ruiz‐Ortega, Marta</creator><creatorcontrib>Rodrigues‐Diez, Raul R. ; Tejera‐Muñoz, Antonio ; Marquez‐Exposito, Laura ; Rayego‐Mateos, Sandra ; Santos Sanchez, Laura ; Marchant, Vanessa ; Tejedor Santamaria, Lucía ; Ramos, Adrian M. ; Ortiz, Alberto ; Egido, Jesus ; Ruiz‐Ortega, Marta</creatorcontrib><description>The COVID‐19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID‐19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID‐19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS‐CoV‐2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well‐known anti‐inflammatory properties of statins, by blocking several molecular mechanisms, including NF‐κB and NLRP3 inflammasomes, could limit the “cytokine storm” in severe COVID‐19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID‐19 outcomes. Linked Articles This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>ISSN: 1476-5381</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.15166</identifier><identifier>PMID: 32562276</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>ACE2 ; Angiotensin-converting enzyme 2 ; Animals ; Autophagy ; Betacoronavirus - isolation &amp; purification ; CD147 antigen ; Coronavirus Infections - drug therapy ; Coronavirus Infections - immunology ; Coronavirus Infections - virology ; Coronaviruses ; COVID-19 ; COVID-19 Drug Treatment ; Cytokine storm ; Cytokines - immunology ; Drug Repositioning ; Epidemiology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration &amp; dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Inflammasomes ; Inflammation ; Lipid rafts ; Molecular modelling ; Pandemics ; Phagocytosis ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - immunology ; Pneumonia, Viral - virology ; Replication ; Review ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Statins ; Themed Issue: Review ; Virus Internalization - drug effects</subject><ispartof>British journal of pharmacology, 2020-11, Vol.177 (21), p.4873-4886</ispartof><rights>2020 The British Pharmacological Society</rights><rights>2020 The British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5136-815459d436264d14fbdd9f3de695953f0448309103ea41bac212615445f9e3683</citedby><cites>FETCH-LOGICAL-c5136-815459d436264d14fbdd9f3de695953f0448309103ea41bac212615445f9e3683</cites><orcidid>0000-0003-2718-3591 ; 0000-0003-4812-1939 ; 0000-0002-2767-0229 ; 0000-0001-6321-2666 ; 0000-0002-1495-6535 ; 0000-0002-2456-6709 ; 0000-0002-9805-9523 ; 0000-0002-7954-5753 ; 0000-0001-6874-2359</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323198/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323198/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32562276$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rodrigues‐Diez, Raul R.</creatorcontrib><creatorcontrib>Tejera‐Muñoz, Antonio</creatorcontrib><creatorcontrib>Marquez‐Exposito, Laura</creatorcontrib><creatorcontrib>Rayego‐Mateos, Sandra</creatorcontrib><creatorcontrib>Santos Sanchez, Laura</creatorcontrib><creatorcontrib>Marchant, Vanessa</creatorcontrib><creatorcontrib>Tejedor Santamaria, Lucía</creatorcontrib><creatorcontrib>Ramos, Adrian M.</creatorcontrib><creatorcontrib>Ortiz, Alberto</creatorcontrib><creatorcontrib>Egido, Jesus</creatorcontrib><creatorcontrib>Ruiz‐Ortega, Marta</creatorcontrib><title>Statins: Could an old friend help in the fight against COVID‐19?</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>The COVID‐19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID‐19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID‐19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS‐CoV‐2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well‐known anti‐inflammatory properties of statins, by blocking several molecular mechanisms, including NF‐κB and NLRP3 inflammasomes, could limit the “cytokine storm” in severe COVID‐19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID‐19 outcomes. Linked Articles This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc</description><subject>ACE2</subject><subject>Angiotensin-converting enzyme 2</subject><subject>Animals</subject><subject>Autophagy</subject><subject>Betacoronavirus - isolation &amp; purification</subject><subject>CD147 antigen</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - immunology</subject><subject>Coronavirus Infections - virology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Drug Treatment</subject><subject>Cytokine storm</subject><subject>Cytokines - immunology</subject><subject>Drug Repositioning</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration &amp; dosage</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Inflammasomes</subject><subject>Inflammation</subject><subject>Lipid rafts</subject><subject>Molecular modelling</subject><subject>Pandemics</subject><subject>Phagocytosis</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - immunology</subject><subject>Pneumonia, Viral - virology</subject><subject>Replication</subject><subject>Review</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statins</subject><subject>Themed Issue: Review</subject><subject>Virus Internalization - drug effects</subject><issn>0007-1188</issn><issn>1476-5381</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kclKxEAQhhtRdFwOvoA0eNFDnK7ekvag6LiCoOBybXqSzqQlk4zpRPHmI_iMPomtM4oK1qUO9dVHFT9C60B2IFR_OCl2QICUc6gHPJaRYAnMox4hJI4AkmQJLXt_T0gYxmIRLTEqJKWx7KHD69a0rvK7eFB3ZYZNhevQ8sbZKsOFLSfYVbgtLM7dqGixGZlAt3hweXd-9PbyCmp_FS3kpvR2bdZX0O3J8c3gLLq4PD0fHFxEqQAmowQEFyrjTFLJM-D5MMtUzjIrlVCC5YTzhBEFhFnDYWhSClSGHS5yZZlM2Aram3on3XBss9RWbWNKPWnc2DTPujZO_55UrtCj-lHHjDJQH4KtmaCpHzrrWz12PrVlaSpbd15TDoKqmDAI6OYf9L7umiq8FygBCiSLRaC2p1Ta1N43Nv8-Boj-SEaHZPRnMoHd-Hn9N_kVRQD6U-DJlfb5f5M-vDqbKt8B2-6VHw</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Rodrigues‐Diez, Raul R.</creator><creator>Tejera‐Muñoz, Antonio</creator><creator>Marquez‐Exposito, Laura</creator><creator>Rayego‐Mateos, Sandra</creator><creator>Santos Sanchez, Laura</creator><creator>Marchant, Vanessa</creator><creator>Tejedor Santamaria, Lucía</creator><creator>Ramos, Adrian M.</creator><creator>Ortiz, Alberto</creator><creator>Egido, Jesus</creator><creator>Ruiz‐Ortega, Marta</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2718-3591</orcidid><orcidid>https://orcid.org/0000-0003-4812-1939</orcidid><orcidid>https://orcid.org/0000-0002-2767-0229</orcidid><orcidid>https://orcid.org/0000-0001-6321-2666</orcidid><orcidid>https://orcid.org/0000-0002-1495-6535</orcidid><orcidid>https://orcid.org/0000-0002-2456-6709</orcidid><orcidid>https://orcid.org/0000-0002-9805-9523</orcidid><orcidid>https://orcid.org/0000-0002-7954-5753</orcidid><orcidid>https://orcid.org/0000-0001-6874-2359</orcidid></search><sort><creationdate>202011</creationdate><title>Statins: Could an old friend help in the fight against COVID‐19?</title><author>Rodrigues‐Diez, Raul R. ; Tejera‐Muñoz, Antonio ; Marquez‐Exposito, Laura ; Rayego‐Mateos, Sandra ; Santos Sanchez, Laura ; Marchant, Vanessa ; Tejedor Santamaria, Lucía ; Ramos, Adrian M. ; Ortiz, Alberto ; Egido, Jesus ; Ruiz‐Ortega, Marta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5136-815459d436264d14fbdd9f3de695953f0448309103ea41bac212615445f9e3683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>ACE2</topic><topic>Angiotensin-converting enzyme 2</topic><topic>Animals</topic><topic>Autophagy</topic><topic>Betacoronavirus - isolation &amp; purification</topic><topic>CD147 antigen</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - immunology</topic><topic>Coronavirus Infections - virology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Drug Treatment</topic><topic>Cytokine storm</topic><topic>Cytokines - immunology</topic><topic>Drug Repositioning</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration &amp; dosage</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Inflammasomes</topic><topic>Inflammation</topic><topic>Lipid rafts</topic><topic>Molecular modelling</topic><topic>Pandemics</topic><topic>Phagocytosis</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - immunology</topic><topic>Pneumonia, Viral - virology</topic><topic>Replication</topic><topic>Review</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statins</topic><topic>Themed Issue: Review</topic><topic>Virus Internalization - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rodrigues‐Diez, Raul R.</creatorcontrib><creatorcontrib>Tejera‐Muñoz, Antonio</creatorcontrib><creatorcontrib>Marquez‐Exposito, Laura</creatorcontrib><creatorcontrib>Rayego‐Mateos, Sandra</creatorcontrib><creatorcontrib>Santos Sanchez, Laura</creatorcontrib><creatorcontrib>Marchant, Vanessa</creatorcontrib><creatorcontrib>Tejedor Santamaria, Lucía</creatorcontrib><creatorcontrib>Ramos, Adrian M.</creatorcontrib><creatorcontrib>Ortiz, Alberto</creatorcontrib><creatorcontrib>Egido, Jesus</creatorcontrib><creatorcontrib>Ruiz‐Ortega, Marta</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rodrigues‐Diez, Raul R.</au><au>Tejera‐Muñoz, Antonio</au><au>Marquez‐Exposito, Laura</au><au>Rayego‐Mateos, Sandra</au><au>Santos Sanchez, Laura</au><au>Marchant, Vanessa</au><au>Tejedor Santamaria, Lucía</au><au>Ramos, Adrian M.</au><au>Ortiz, Alberto</au><au>Egido, Jesus</au><au>Ruiz‐Ortega, Marta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statins: Could an old friend help in the fight against COVID‐19?</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2020-11</date><risdate>2020</risdate><volume>177</volume><issue>21</issue><spage>4873</spage><epage>4886</epage><pages>4873-4886</pages><issn>0007-1188</issn><issn>1476-5381</issn><eissn>1476-5381</eissn><abstract>The COVID‐19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID‐19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID‐19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS‐CoV‐2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well‐known anti‐inflammatory properties of statins, by blocking several molecular mechanisms, including NF‐κB and NLRP3 inflammasomes, could limit the “cytokine storm” in severe COVID‐19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID‐19 outcomes. Linked Articles This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>32562276</pmid><doi>10.1111/bph.15166</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-2718-3591</orcidid><orcidid>https://orcid.org/0000-0003-4812-1939</orcidid><orcidid>https://orcid.org/0000-0002-2767-0229</orcidid><orcidid>https://orcid.org/0000-0001-6321-2666</orcidid><orcidid>https://orcid.org/0000-0002-1495-6535</orcidid><orcidid>https://orcid.org/0000-0002-2456-6709</orcidid><orcidid>https://orcid.org/0000-0002-9805-9523</orcidid><orcidid>https://orcid.org/0000-0002-7954-5753</orcidid><orcidid>https://orcid.org/0000-0001-6874-2359</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 2020-11, Vol.177 (21), p.4873-4886
issn 0007-1188
1476-5381
1476-5381
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7323198
source Wiley; PubMed Central(OpenAccess)
subjects ACE2
Angiotensin-converting enzyme 2
Animals
Autophagy
Betacoronavirus - isolation & purification
CD147 antigen
Coronavirus Infections - drug therapy
Coronavirus Infections - immunology
Coronavirus Infections - virology
Coronaviruses
COVID-19
COVID-19 Drug Treatment
Cytokine storm
Cytokines - immunology
Drug Repositioning
Epidemiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Inflammasomes
Inflammation
Lipid rafts
Molecular modelling
Pandemics
Phagocytosis
Pneumonia, Viral - drug therapy
Pneumonia, Viral - immunology
Pneumonia, Viral - virology
Replication
Review
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Statins
Themed Issue: Review
Virus Internalization - drug effects
title Statins: Could an old friend help in the fight against COVID‐19?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T13%3A30%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statins:%20Could%20an%20old%20friend%20help%20in%20the%20fight%20against%20COVID%E2%80%9019?&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Rodrigues%E2%80%90Diez,%20Raul%20R.&rft.date=2020-11&rft.volume=177&rft.issue=21&rft.spage=4873&rft.epage=4886&rft.pages=4873-4886&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.15166&rft_dat=%3Cproquest_pubme%3E2415297031%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5136-815459d436264d14fbdd9f3de695953f0448309103ea41bac212615445f9e3683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2451916375&rft_id=info:pmid/32562276&rfr_iscdi=true